Onyx Pharmaceuticals price target lowered to $96 from $99 at RW Baird Baird lowered its price target on Onyx Pharmaceuticals to reflect the dilutive nature of its secondary offering. The firm has no change to its positive stance and remains buyers of the shares citing bullish signals from its recent Kyprolis survey which is expected to ramp in 2013. Shares are Outperform rated.
News For ONXX From The Last 14 Days
Check below for free stories on ONXX the last two weeks.